Background
Methods
Patients and follow-up
Measurement of big-ET, hs-CRP and NT pro-BNP
Statistical analysis
Results
Value of NT pro-BNP, hs-CRP and big-ET in predicting all-cause mortality
Characteristics of the study population
All of the patients (n = 560) | NTpro-BNP < 2247 pmol/mL (n = 362) | NT pro-BNP > 2247 pmol/mL (n = 198) |
P value | |
---|---|---|---|---|
Age (years) | 51.0 ± 14.2 | 51.1 ± 13.4 | 51.0 ± 15.8 | 0.958 |
Female sex, n (%) | 146 (26.1) | 98 (27.1) | 48 (24.2) | 0.466 |
History | ||||
Course | 3 (0.5-7) | 2 (0.35-7) | 3 (0.6375-6) | 0.909 |
Diabetes mellitus | 83 (14.8) | 58 (16.0) | 25 (12.6) | 0.280 |
Atrial fibrillation, n (%) | 121 (21.6) | 76 (21.0) | 45 (22.7) | 0.634 |
Smoker, n (%)2
| 265 (47.3) | 169 (46.8) | 96 (48.9) | 0.625 |
Drinker, n (%)2
| 170 (30.4) | 119 (32.9) | 51 (26.0) | 0.089 |
NYHA class III and IV, n (%)3
| 425 (75.9) | 247 (68.2) | 178 (89.9) |
<0.001
|
Admission vital signs | ||||
SBP (mm Hg)3
| 113.3 ± 17.7 | 116.0 ± 17.6 | 108.3 ± 16.7 |
<0.001
|
DBP (mm Hg)3
| 72.3 ± 12.6 | 73.3 ± 12.5 | 70.5 ± 12.5 |
0.012
|
Heart rate, beat/min | 80.8 ± 17.1 | 79.1 ± 16.0 | 84.0 ± 18.6 |
0.002
|
Laboratory values at admission2
| ||||
Glucose (mmol/L) | 5.53 ± 1.70 | 5.49 ± 1.43 | 5.62 ± 2.10 | 0.386 |
TG (mmol/L)3
| 1.58 ± 0.89 | 1.74 ± 0.99 | 1.27 ± 0.57 |
<0.001
|
TC (mmol/L)3
| 4.59 ± 1.11 | 4.78 ± 1.08 | 4.22 ± 1.07 |
<0.001
|
Creatinine (μmol/L) | 91.9 ± 34.2 | 87.5 ± 26.5 | 100.0 ± 44.0 |
<0.001
|
BUN (μmol/L)3
| 8.02 ± 4.07 | 7.68 ± 3.90 | 8.63 ± 4.33 |
0.010
|
NT Pro-BNP (pmol/mL)3
| 1652.85 (837.375-2907.2) | 1051.45 (700.7-1613.675) | 3425.25 (2787.975-4713.125) |
<0.001
|
Electrocardiogram data4
| ||||
QRS duration (ms) | 119.6 ± 30.1 | 117.6 ± 28.3 | 123.4 ± 33.0 |
0.029
|
QT (ms) | 408.0 ± 50.7 | 410.9 ± 49.6 | 402.6 ± 52.4 | 0.067 |
Echocardiography data4
| ||||
LV (mm)3
| 68.5 ± 9.5 | 67.1 ± 8.7 | 71.1 ± 10.3 |
<0.001
|
LVEF (mm)3
| 31.1 ± 8.4 | 32.6 ± 8.4 | 28.1 ± 7.6 |
<0.001
|
RV (mm) | 24.2 ± 5.4 | 23.1 ± 4.9 | 26.2 ± 5.8 |
<0.001
|
LA (mm)3
| 44.5 ± 7.8 | 42.9 ± 7.7 | 47.4 ± 7.2 |
<0.001
|
Medicine at admission2
| ||||
Diuretics, n (%) | 529 (94.5) | 339 (94.4) | 190 (97.4) | 0.103 |
ACEI/ARB, n (%)3
| 473 (84.5) | 315 (87.5) | 158 (81.9) | 0.073 |
Beta-blockers, n (%) | 509 (90.9) | 340 (94.4) | 169 (87.1) |
0.003
|
Digoxin, n (%) | 449 (80.2) | 280 (78.0) | 169 (86.7) |
0.013
|
Aspirin/anticoagulation n (%) | 353 (63.0) | 243 (67.5) | 110 (56.4) |
0.010
|
Spironolactone, n (%) | 514 (91.8) | 331 (91.9) | 183 (93.8) | 0.414 |
Relation between NT pro-BNP, hs-CRP, big-ET levels and all-cause mortality
Cox proportional hazard models
All of the patients (n = 622) | hs-CRP < 3.91 mg/L (n = 375) | hs-CRP > 3.91 mg/L (n = 247) |
P value | Big ET < 0.95 pmol/mL (n = 335) | Big ET > 0.95 pmol/mL (n = 287) |
P value | |
---|---|---|---|---|---|---|---|
Age (years) | 50.1 ± 14.3 | 50.1 ± 14.1 | 52.5 ± 14.2 | 0.051 | 51.2 ± 14.1 | 51.0 ± 14.5 | 0.846 |
Female sex, n (%) | 160 (25.7) | 102 (27.2) | 58 (23.5) | 0.299 | 88 (26.3) | 72 (25.1) | 0.737 |
History | |||||||
Course | 3 (0.5-7) | 2 (0.35-7) | 3 (0.6-6) | 0.170 | 3 (0.5-6) | 2.5 (0.35-7) | 0.628 |
Diabetes mellitus | 92 (14.8) | 57 (15.2) | 35 (14.2) | 0.723 | 45 (13.4) | 47 (16.4) | 0.303 |
Atrial fibrillation, n (%) | 142 (22.8) | 79 (21.1) | 63 (25.5) | 0.197 | 62 (18.5) | 80 (27.9) |
0.006
|
Smoker, n (%)2
| 294 (47.3) | 172 (45.9) | 122 (49.4) | 0.396 | 159 (47.5) | 135 (47.0) | 0.953 |
Drinker, n (%)2
| 190 (30.5) | 119 (31.7) | 71 (28.7) | 0.422 | 103 (30.7) | 87 (30.3) | 0.933 |
NYHA class III and IV, n (%)3
| 468 (75.2) | 250 (66.7) | 218 (88.3) |
<0.001
| 217 (64.8) | 251 (87.5) |
<0.001
|
Admission vital signs | |||||||
SBP (mm Hg)3
| 113.2 ± 17.7 | 115.0 ± 31.1 | 118.7 ± 29.4 |
0.002
| 116.1 ± 17.6 | 109.7 ± 17.1 |
<0.001
|
DBP (mm Hg)3
| 72.2 ± 12.6 | 73.4 ± 12.1 | 70.4 ± 13.1 |
0.004
| 72.9 ± 12.2 | 71.4 ± 13.1 | 0.135 |
Heart rate, beat/min | 80.5 ± 17.2 | 78.3 ± 16.2 | 83.9 ± 18.1 |
<0.001
| 78.7 ± 16.6 | 71.4 ± 13.1 |
0.004
|
Laboratory values at admission4
| |||||||
Glucose (mmol/L) | 5.52 ± 1.66 | 5.44 ± 1.39 | 5.64 ± 1.99 | 0.154 | 5.57 ± 1.65 | 5.46 ± 1.66 | 0.425 |
TG (mmol/L)3
| 1.58 ± 0.90 | 1.68 ± 1.00 | 1.41 ± 0.69 |
<0.001
| 1.74 ± 0.94 | 1.38 ± 0.81 |
<0.001
|
TC (mmol/L)3
| 4.57 ± 1.11 | 4.68 ± 1.02 | 4.40 ± 1.22 |
0.004
| 4.84 ± 1.06 | 4.25 ± 1.09 |
<0.001
|
Creatinine (μmol/L) | 92.3 ± 34.7 | 88.2 ± 29.9 | 98.4 ± 40.3 |
0.001
| 89.0 ± 28.5 | 96.1 ± 40.6 |
0.011
|
BUN (μmol/L)3
| 8.02 ± 4.09 | 7.89 ± 4.21 | 8.22 ± 3.89 | 0.328 | 7.96 ± 4.10 | 8.10 ± 4.07 | 0.666 |
NT Pro-BNP (pmol/mL)3
| 1652.85 (837.375-2907.2) | 1367 (736.75-2259.4) | 2281.5 (1218.1-3589.4) |
<0.001
| 1089 (714.675-1949.1) | 2529.05 (1439.1-3608.475) |
<0.001
|
Electrocardiogram data2
| |||||||
QRS duration (ms) | 119.2 ± 30.4 | 119.6 ± 31.1 | 118.7 ± 29.4 | 0.720 | 119.4 ± 30.2 | 119.0 ± 30.7 | 0.883 |
QT (ms) | 407.7 ± 51.0 | 411.9 ± 50.5 | 401.2 ± 51.1 |
0.011
| 413.9 ± 49.6 | 400.4 ± 51.7 |
0.001
|
Echocardiography data4
| |||||||
LV (mm)3
| 68.3 ± 9.5 | 67.8 ± 9.5 | 69.3 ± 9.4 | 0.055 | 67.3 ± 8.9 | 69.5 ± 10.1 |
0.005
|
LVEF (mm)3
| 31.2 ± 8.5 | 32.2 ± 8.7 | 29.8 ± 7.9 |
0.001
| 33.0 ± 8.5 | 29.2 ± 7.9 |
<0.001
|
RV (mm) | 24.2 ± 5.5 | 23.3 ± 5.0 | 25.5 ± 5.9 |
<0.001
| 22.6 ± 4.2 | 26.0 ± 6.1 |
<0.001
|
LA (mm)3
| 44.4 ± 7.8 | 43.1 ± 7.6 | 46.5 ± 7.8 |
<0.001
| 42.3 ± 7.2 | 46.9 ± 7.8 |
<0.001
|
Medicine at admission2
| |||||||
Diuretics, n (%) | 589 (94.7) | 352 (93.9) | 237 (96.0) | 0.080 | 314 (93.7) | 275 (95.8) |
0.048
|
ACEI/ARB, n (%)3
| 522 (83.9) | 330 (88.0) | 192 (77.7) |
0.003
| 289 (86.3) | 233 (81.2) | 0.126 |
Beta-blockers, n (%) | 564 (90.7) | 349 (93.1) | 215 (87.0) |
0.038
| 306 (91.3) | 258 (89.9) | 0.857 |
Digoxin, n (%) | 497 (79.9) | 287 (76.5) | 210 (85.0) |
0.004
| 259 (77.3) | 238 (82.9) |
0.038
|
Aspirin/anticoagulation n (%) | 393 (63.2) | 237 (63.2) | 156 (63.2) | 0.868 | 211 (63.0) | 182 (63.4) | 0.725 |
Spironolactone, n (%) | 572 (92.0) | 347 (92.5) | 225 (91.1) | 0.837 | 306 (91.3) | 266 (92.7) | 0.193 |